Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · IEX Real-Time Price · USD
1.065
-0.025 (-2.29%)
Apr 25, 2024, 1:15 PM EDT - Market open
Karyopharm Therapeutics Stock Forecast
KPTI's stock price has decreased by -72.27% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for KPTI stock have an average target of 5.67, with a low estimate of 3.00 and a high estimate of 10. The average target predicts an increase of 432.39% from the current stock price of 1.07.
Analyst Consensus: Buy
* Price targets were last updated on Mar 1, 2024.
Analyst Ratings
The average analyst rating for KPTI stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $8 | Strong Buy | Maintains | $10 → $8 | +651.17% | Mar 1, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +369.48% | Nov 3, 2023 |
| RBC Capital | RBC Capital | Buy Maintains $4 → $3 | Buy | Maintains | $4 → $3 | +181.69% | Nov 3, 2023 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $5 → $4 | Hold | Maintains | $5 → $4 | +275.59% | Aug 7, 2023 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $7 | Buy | Maintains | $8 → $7 | +557.28% | Aug 3, 2023 |
Financial Forecast
Revenue This Year
149.45M
from 146.03M
Increased by 2.34%
Revenue Next Year
168.04M
from 149.45M
Increased by 12.44%
EPS This Year
-1.25
from -1.25
EPS Next Year
-1.03
from -1.25
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 158.4M | 220.2M | 277.1M | 469.7M | 646.1M |
| Avg | 149.5M | 168.0M | 235.9M | 324.3M | 447.2M |
| Low | 139.6M | 127.6M | 192.7M | 245.9M | 334.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 8.5% | 47.3% | 64.9% | 99.1% | 99.2% |
| Avg | 2.3% | 12.4% | 40.4% | 37.5% | 37.9% |
| Low | -4.4% | -14.6% | 14.7% | 4.3% | 3.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.14 | -0.81 | -0.44 | 0.29 | 1.05 |
| Avg | -1.25 | -1.03 | -0.59 | -0.02 | 0.34 |
| Low | -1.30 | -1.24 | -0.70 | -0.22 | -0.02 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.